Literature DB >> 29752455

HCV therapy and risk of liver cancer recurrence: who to treat?

Massimo Colombo1,2, Vincenzo Boccaccio3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29752455     DOI： 10.1038/s41575-018-0018-5

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  5 in total

1.  High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals.

Authors:  Anne F Pihl; Anna F Offersgaard; Christian K Mathiesen; Jannick Prentoe; Ulrik Fahnøe; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Sci Rep       Date:  2018-11-30       Impact factor: 4.379

2.  Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification-Lateral Flow Dipstick.

Authors:  Haili Wang; Yuhang Zhang; Jingming Zhou; Ming Li; Yumei Chen; Yankai Liu; Hongliang Liu; Peiyang Ding; Chao Liang; Xifang Zhu; Ying Zhang; Cheng Xin; Gaiping Zhang; Aiping Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-02-17       Impact factor: 5.293

Review 3.  Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma.

Authors:  Saleh A Alqahtani; Massimo Colombo
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

4.  Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients.

Authors:  Solomon Owusu Sekyere; Kerstin Port; Katja Deterding; Markus Cornberg; Heiner Wedemeyer
Journal:  United European Gastroenterol J       Date:  2021-02-18       Impact factor: 4.623

Review 5.  Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents.

Authors:  Marco Sanduzzi-Zamparelli; Loreto Boix; Cassia Leal; María Reig
Journal:  Viruses       Date:  2019-05-01       Impact factor: 5.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.